Bioventus Inc.BVSNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank75
5Y CAGR-13.1%
Studio
Year-over-Year Change

Price-to-earnings ratio

5Y CAGR
-13.1%/yr
Long-term compound
Percentile
P75
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive growthElevated
PeriodValueYoY Change
202521.81+206.6%
2024-20.46-868.1%
2023-2.11-109.3%
2022-1.01-103.0%
202134.01-22.9%
202044.13-72.3%
2019159.34+278.2%
2018-89.43+86.6%
2017-666.02-995.4%
2016-60.80-